Science Highlights
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
10 July 2023
The fabrication of a particular device depends heavily on the immobilization of the biosensing element (a probe such as an antibody, aptamer, etc.) onto the transducer […]
27 March 2023
Celtarys Research collaborates with several research groups in Europe for the validation of our products in different assays commonly used in drug discovery, always with the […]
7 March 2023
A different way to monitor GPCR binding, target engagement and internalization with a new fluorescent-conjugate toolbox. The past decade has witnessed fluorescently tagged drug molecules gaining […]
27 January 2023
WHY IS IMPORTANT TO CONSIDER MULTIPLE ASSAY TYPES FOR TARGETS CHARACTERIZATION? Usually, in the identification of new drug-like molecules for a target of interest it is […]
26 January 2023
Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
20 December 2022
Malignant cells often hijack the normal physiological functions of GPCRs to survive, proliferate autonomously, evade the immune system, increase their blood supply, invade their surrounding tissues […]
7 November 2022
Cannabinoid receptors, CB1 and CB2 are two extensively studied targets of the GPCR family for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, […]